Investigational drugs for anxiety in patients with schizophrenia

Expert Opinion on Investigational Drugs
Ricardo P GarayPierre-Michel Llorca

Abstract

Anxiety is a frequent symptom of schizophrenia, which is highly associated with an increased risk of relapse and suicide. The effect of antipsychotics on this clinical dimension is not specific and the common practice of prescribing benzodiazepines remains unsatisfactory. The authors review recent well-designed clinical trials for anxiety in patients with schizophrenia. The content includes information derived from trial databases, regulatory authorities and scientific literature. Anxiety in schizophrenia has severe consequences and specific clinical features, which require a specific therapy, beyond benzodiazepines. In these past 2 years, two compounds (the anticonvulsant/anxiolytic pregabalin and the atypical antipsychotic quetiapine) were on Phase III/IV clinical trials for schizophrenia, with comorbid anxiety as a primary outcome measure. Potential for success is high, given their strong rationale and the clinical experience with both drugs. Anxiety (as a symptom) was a secondary outcome measure in trials for schizophrenia involving seven other compounds (lurasidone, amisulpride, bitopertin, oxytocin, famotidine, cannabidiol and the L-theanine and pregnenolone combination). Primary completion date is expected in the next 2 ...Continue Reading

References

Nov 19, 2015·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Oct 16, 2015·Acta Neuropsychiatrica·Artur PalaszRyszard Wiaderkiewicz
Apr 29, 2015·Expert Review of Clinical Pharmacology·Mathias Zink, Christoph U Correll
May 28, 2016·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Nov 8, 2017·Current Psychiatry Reports·Baptiste PignonAntoine Pelissolo
Oct 21, 2015·CNS Drugs·Henk Temmingh, Dan J Stein
Apr 23, 2020·Annals of General Psychiatry·Kalai NaiduLizelle Fletcher

Citations

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 20, 1999·Neuropsychobiology·P BoyerO Fleurot
Jul 20, 1999·The Annals of Pharmacotherapy·M C Martinez
Dec 17, 2004·International Clinical Psychopharmacology·John J WorthingtonMark H Pollack
Apr 7, 2007·Journal of Clinical Psychopharmacology·Matthew A MenzaHumberto Marin
Sep 21, 2007·Current Psychiatry Reports·Jonathan M Amiel, Sanjay J Mathew
Oct 9, 2007·Acta Psychiatrica Scandinavica·S LeuchtN Sartorius
Jul 23, 2008·European Journal of Pharmacology·Nobuaki EgashiraMichihiro Fujiwara
May 15, 2009·Journal of Clinical Psychopharmacology·Robert G SternAnthony Tobia
May 20, 2009·Pharmacopsychiatry·C Schönfeldt-LecuonaR W Freudenmann
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananSchizophrenia Patient Outcomes Research Team (PORT)
Jun 10, 2010·Journal of Clinical Psychopharmacology·Susanne EnglischMathias Zink
Jun 29, 2010·Trends in Pharmacological Sciences·Caline S KaramJonathan A Javitch
Sep 11, 2010·Journal of Psychopharmacology·José Alexandre S CrippaJaime Eduardo Cecílio Hallak
Oct 1, 2010·Clinical Schizophrenia & Related Psychoses·Joshua T Kantrowitz, Daniel C Javitt
Feb 11, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mateus M BergamaschiJosé Alexandre S Crippa
Jul 15, 2011·Therapeutics and Clinical Risk Management·Ludovic SamalinPierre-Michel Llorca
Oct 18, 2011·Pharmacological Reports : PR·Kinga BurdaJennifer Zin
Dec 14, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David Feifel
Mar 8, 2012·The Annals of Pharmacotherapy·Terri M WenselMarshall E Cates
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Sep 15, 2012·Trends in Neurosciences·Inga D Neumann, Rainer Landgraf
Mar 28, 2013·Current Psychiatry Reports·Stefano PallantiGiacomo Grassi
Apr 18, 2013·CNS Spectrums·Stephen M StahlKatherine D Warburton
Jun 15, 2013·Journal of Clinical Psychopharmacology·Katarina MeskanenJesper Ekelund
Jun 19, 2013·European Archives of Psychiatry and Clinical Neuroscience·Pierre-Michel LlorcaFranck J Bayle
Jun 27, 2013·Schizophrenia Research·Rajiv TandonWilliam Carpenter
Jul 10, 2013·Neuropsychiatric Disease and Treatment·David S BaldwinRizwan Rafiq
Jul 11, 2013·Expert Opinion on Drug Discovery·Frank I Tarazi, Marco A Riva
Aug 13, 2013·Psychiatry Research·Raphael J BragaSamuel G Siris
Jun 1, 2012·Therapeutic Advances in Psychopharmacology·Laura Christina WittkampfMarike Lancel
Dec 7, 2013·Expert Review of Neurotherapeutics·Charlotte BothChristian Lange-Asschenfeldt

Related Concepts

Amisulpride
Atypical Antipsychotic [EPC]
Anticonvulsants
Pregnenolone
Schizophrenia
Lurasidone
Aripiprazole
Theanine
Antipsychotic Agents
Oxytocin

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here